International Journal of Radiology and Diagnostic Imaging



E-ISSN: 2664-4444
P-ISSN: 2664-4436
Impact Factor (RJIF): 5.68
www.radiologypaper.com
IJRDI 2025; 8(3): 146-149
Received: 13-06-2025
Accepted: 17-07-2025

Dr. Ishaan Bakshi
MBBS; MBA Y1 (Healthcare), Radiology Integrated Training Initiative (R-ITI), Royal College of Radiologists, Dr. DY Patil University, Pune, Maharashtra, India

Corresponding Author:
Dr. Ishaan Bakshi
MBBS; MBA Y1 (Healthcare), Radiology Integrated Training Initiative (R-ITI), Royal College of Radiologists, Dr. DY Patil University, Pune, Maharashtra, India

Utilizing AI in treatment planning and outcome prediction: Leveraging radiomics for personalized treatment analysis

Ishaan Bakshi

DOI: https://www.doi.org/10.33545/26644436.2025.v8.i3c.487

Abstract
Artificial intelligence (AI) has rapidly emerged as a transformative tool in oncological imaging, particularly when integrated with radiomics. By extracting high-dimensional quantitative features from medical images, radiomics enables the characterization of tumor heterogeneity beyond visual assessment. Incorporating AI-driven analytics into this process offers a unique opportunity to optimize treatment planning and predict clinical outcomes more accurately. This study reviews recent advances in AI-assisted radiomics for treatment planning and outcome prediction. We highlight data acquisition, feature extraction, model development, and validation frameworks that integrate imaging biomarkers with clinical and molecular profiles. The strengths and limitations of machine learning and deep learning models in personalized treatment analysis are critically evaluated. Evidence demonstrates that AI-enhanced radiomics can improve prognostic modeling, stratify patients into risk categories, and guide individualized treatment decisions. Models combining radiomics with genomic and clinical data consistently outperform conventional prognostic methods. Despite promising results, challenges such as data standardization, reproducibility, and clinical translation remain. AI-driven radiomics holds substantial potential to advance precision medicine by personalizing treatment strategies and predicting outcomes with higher accuracy. Future efforts should focus on multi-institutional validation, explainable AI frameworks, and integration into clinical workflows to ensure widespread adoption.

Keywords: Artificial intelligence, radiomics, treatment planning, outcome prediction, personalized medicine

Introduction

The evolution of medical imaging has expanded far beyond visual interpretation, ushering in an era where advanced computational techniques enable the extraction of hidden quantitative information from images. Radiomics, defined as the high-throughput extraction of imaging features, has emerged as a cornerstone in this paradigm shift. By capturing tumor heterogeneity, vascularity, and micro environmental characteristics that are imperceptible to the human eye, radiomics provides a rich data source for precision oncology.

Parallel to these advances, artificial intelligence (AI) has demonstrated transformative capabilities across healthcare, particularly in pattern recognition, predictive modeling, and decision support. The convergence of AI and radiomics has created a powerful framework for individualized treatment planning and outcome prediction. Leveraging machine learning and deep learning approaches, AI-driven radiomics can identify prognostic biomarkers, predict therapeutic response, and support risk-adapted treatment strategies.

Personalized treatment planning is especially crucial in oncology, where heterogeneity in tumor biology and patient response often limits the effectiveness of conventional approaches. Traditional prognostic models based on clinical and pathological variables frequently lack the sensitivity required for tailored therapies. In contrast, AI-integrated radiomics enables data-driven insights that complement molecular profiling, offering a multidimensional approach to treatment optimization.

This article explores the utilization of AI in treatment planning and outcome prediction, focusing on the role of radiomics as a bridge between imaging and precision medicine. We present current methodologies, discuss key findings from recent literature, and highlight ongoing challenges and opportunities for clinical translation.

Materials and Methods

This study was designed as a narrative review to evaluate the role of artificial intelligence (AI) integrated with radiomics in treatment planning and outcome prediction. A comprehensive search of PubMed, Scopus, Web of Science, and IEEE Xplore databases was conducted up to June 2025, using a combination of keywords such as *"artificial intelligence," "radiomics," "treatment planning," "outcome prediction,"* and *"personalized medicine."* Boolean operators and Medical Subject Headings (MeSH) terms were applied to maximize sensitivity, and the reference lists of retrieved articles were screened to capture additional relevant publications.

Eligible studies included original research articles and systematic evaluations that reported the application of AI-based radiomics for clinical decision-making, specifically in the domains of outcome prediction or personalized treatment planning. Only English-language articles were considered, while case reports with fewer than ten patients, conference abstracts, and studies unrelated to AI or radiomics were excluded. For each study meeting the inclusion criteria, data were extracted regarding imaging modalities, tumor sites, radiomic features analyzed, types of AI algorithms employed, validation strategies, and clinical endpoints such as treatment response, survival, or toxicity prediction.

The synthesis of evidence was performed qualitatively, with emphasis on methodological consistency, clinical relevance, and translational potential. To provide clarity on current practices, an AI-radiomics workflow was reconstructed based on reviewed literature. This workflow typically begins with standardized image acquisition and preprocessing, followed by segmentation of regions of interest and extraction of high-dimensional quantitative features encompassing first-order statistics, texture, shape, and wavelet-based descriptors. Feature selection and reduction techniques, such as least absolute shrinkage and selection operator (LASSO), principal component analysis (PCA), or random forest ranking, are then applied to mitigate redundancy and overfitting. Predictive modeling is usually performed using supervised or unsupervised machine learning methods, ensemble algorithms, or deep neural networks, and validated either through internal cross-validation or independent external datasets. Finally, outputs from these models are considered in the context of clinical decision support, enabling more individualized treatment planning and outcome prediction.

Results

The literature reviewed demonstrates substantial progress in applying AI-driven radiomics to treatment planning and outcome prediction across multiple oncological domains. Most studies reported that radiomics features, when integrated with machine learning or deep learning models, provided greater prognostic and predictive power compared to conventional clinical and pathological parameters alone. Imaging modalities such as CT, MRI, and PET were most frequently utilized, with MRI-based radiomics showing particular utility in characterizing tumor heterogeneity and predicting response to therapy in brain and breast cancers, while PET and CT radiomics were often employed in lung, head and neck, and gastrointestinal malignancies.

Several studies highlighted that combining radiomic features with clinical and genomic data further enhanced predictive accuracy. Multimodal models integrating imaging biomarkers with molecular signatures consistently outperformed single-modality approaches, particularly in predicting overall survival, progression-free survival, and response to chemo radiotherapy. Deep learning methods, especially convolutional neural networks (CNNs), demonstrated strong performance in automated feature extraction and classification tasks, often reducing the need for handcrafted feature engineering. However, traditional machine learning techniques such as random forests, support vector machines (SVM), and logistic regression also remained widely used, especially in studies with limited datasets.

Validation strategies varied across studies, with many employing internal cross-validation, while fewer reported external validation using independent cohorts. Importantly, those with external validation demonstrated greater generalizability and clinical reliability, though such studies remain limited in number. Despite methodological differences, a recurring finding was that AI-enhanced radiomics models were able to stratify patients into risk categories with higher precision, identify potential responders and non-responders to targeted therapies or immunotherapy, and predict treatment-related toxicities more accurately than standard models.

Nevertheless, challenges were frequently reported, including heterogeneity in imaging acquisition protocols, lack of standardization in feature extraction, and the risk of overfitting when using small sample sizes. While multi-institutional studies showed promise in addressing these issues, their number remains comparatively small. Collectively, the available evidence underscores that AI-powered radiomics not only refines prognostic modeling but also represents a tangible step toward clinically actionable personalized treatment strategies.

Discussion

The findings of this review underscore the transformative role that artificial intelligence, particularly when combined with radiomics, can play in advancing precision medicine. Radiomics has the unique ability to quantify imaging features that go far beyond visual inspection, capturing the spatial complexity, heterogeneity, and microenvironmental signatures of tumors. When these high-dimensional data are processed through AI algorithms, they generate robust predictive models that can guide clinicians in making more accurate and individualized treatment decisions. This synergy is increasingly recognized as a paradigm shift in oncology, moving clinical decision-making from a population-based approach toward truly personalized care.

One of the most striking observations from the reviewed studies is the superiority of multimodal data integration. Traditional prognostic models, which rely solely on clinical and histopathological features, often lack the resolution to account for the biological diversity of cancers. By incorporating radiomics with clinical records, laboratory data, and genomic or proteomic information, AI-driven models achieve higher predictive accuracy and clinical relevance. For instance, combining CT-based radiomic features with molecular biomarkers has shown promise in predicting immunotherapy response in lung cancer, while MRI-radiomics integrated with genomic signatures has been valuable in glioblastoma stratification. This multidimensional approach not only improves outcome

prediction but also facilitates risk-adapted treatment strategies, where therapy intensity can be modulated according to predicted response or toxicity risk.

The methodological advances are equally noteworthy. While classical machine learning algorithms such as support vector machines and random forests have demonstrated utility, deep learning models, particularly convolutional neural networks (CNNs), have redefined the field by automating feature selection and capturing nonlinear associations. These models have achieved state-of-the-art performance in outcome prediction across several tumor types. However, their complexity introduces interpretability challenges. Clinicians often view deep learning as a "black box," which hinders trust and adoption in clinical workflows. This highlights the importance of developing explainable AI (XAI) frameworks that can provide interpretable outputs, such as feature importance maps or decision confidence scores, enabling clinicians to better understand and validate model predictions.

Despite these encouraging advances, several barriers impede clinical translation. A major limitation lies in the heterogeneity of imaging protocols across institutions. Variations in scanner types, acquisition parameters, and reconstruction algorithms can lead to inconsistent feature values, undermining reproducibility. Similarly, differences in segmentation techniques—manual versus automated—can introduce variability that impacts feature stability. Addressing these challenges requires rigorous standardization initiatives, such as the Image Biomarker Standardisation Initiative (IBSI), and wider adoption of harmonization methods to ensure comparability of results across studies and centers.

Another recurring concern is the relatively small sample size in many studies, which increases the risk of model overfitting and limits external validity. While internal validation techniques such as cross-validation are frequently employed, only a minority of studies perform independent external validation using large, multi-institutional cohorts. Without such validation, the clinical reliability of AI-radiomics models remains uncertain. Collaborative data-sharing initiatives, federated learning frameworks, and establishment of international radiomics consortia may provide pathways to overcome these limitations by enabling access to diverse and sufficiently powered datasets.

Beyond technical and methodological issues, ethical and regulatory considerations warrant careful attention. AI models trained on limited or biased datasets may inadvertently perpetuate inequities, leading to systematic disadvantages for underrepresented populations. Ensuring fairness, transparency, and inclusivity in model development is therefore crucial. Patient data privacy also remains a significant challenge, particularly as multi-institutional collaborations grow. The adoption of secure, privacy-preserving techniques such as federated learning, alongside adherence to international data governance frameworks, will be essential for safe and ethical AI deployment in healthcare. Regulatory bodies such as the FDA and EMA are beginning to issue guidelines for AI-driven medical tools, but a globally harmonized regulatory pathway is still evolving.

Clinically, the implications of AI-enhanced radiomics are profound. In radiotherapy, for example, predictive models could enable adaptive planning by forecasting treatment response and toxicity risk before or during therapy. In systemic therapies such as immunotherapy or chemotherapy, radiomics may help identify patients most likely to benefit, thereby sparing others from unnecessary side effects and financial burden. The potential for real-time decision support tools integrated into radiology and oncology workflows could accelerate clinical adoption, especially if designed with user-friendly interfaces and validated across diverse populations.

Looking ahead, future research must prioritize three key areas: standardization, scalability, and interpretability. First, standardized imaging and feature extraction protocols will be vital to ensure reproducibility and comparability across studies. Second, large-scale, multi-institutional collaborations are needed to generate sufficiently diverse datasets for robust external validation. Third, the development of explainable AI systems will play a pivotal role in fostering clinician trust and enabling regulatory approval. Furthermore, hybrid models that combine handcrafted radiomics features with deep learning-derived representations may offer the best of both worlds, balancing interpretability with predictive power.

In summary, while current limitations remain significant, the integration of AI and radiomics represents a tangible step toward realizing the vision of personalized oncology. By addressing technical, methodological, and ethical challenges, and by fostering collaborations across disciplines, AI-radiomics has the potential to transition from experimental studies to routine clinical practice, ultimately improving patient outcomes and advancing the field of precision medicine.

Future Directions

The field of AI-enhanced radiomics is still in its formative stages, and several promising avenues for advancement are emerging. First, the development of standardized imaging protocols and feature extraction pipelines will be critical to ensure reproducibility across institutions. Initiatives such as the Image Biomarker Standardisation Initiative (IBSI) should be expanded and widely adopted to harmonize methodologies. Second, large-scale, multi-center collaborations must be prioritized to generate diverse datasets that allow for robust training and external validation of predictive models. Federated learning frameworks, which enable institutions to train models collaboratively without sharing raw patient data, represent an innovative solution to overcome privacy concerns and promote inclusivity.

Another key direction involves the integration of explainable AI (XAI) into radiomics workflows. Models capable of providing transparent rationale for their predictions will improve clinician confidence and facilitate regulatory approval. Visualization tools such as saliency maps or feature attribution methods could make AI outputs more interpretable and clinically actionable. Additionally, hybrid modeling strategies that combine handcrafted radiomics features with deep learning-derived representations may offer a balance between interpretability and predictive performance.

Finally, the clinical translation of AI-radiomics models will require integration into real-time decision support systems embedded within oncology workflows. Seamless interoperability with electronic health records, radiology systems, and treatment planning platforms will be essential for widespread adoption. Pilot studies evaluating AI-

radiomics models in prospective clinical trials should also be pursued, as they will provide the highest level of evidence regarding clinical utility and patient benefit.

Conclusion

Artificial intelligence-driven radiomics represents a powerful and rapidly evolving approach to personalized treatment planning and outcome prediction. By extracting high-dimensional features from medical images and leveraging advanced computational models, AI enhances our ability to capture tumor heterogeneity, stratify risk, and guide individualized therapy decisions. Evidence to date consistently demonstrates that AI-radiomics outperforms conventional prognostic methods, particularly when integrated with clinical and molecular data.

Despite its promise, challenges such as imaging standardization, data heterogeneity, limited external validation, and interpretability issues must be addressed before clinical implementation can be realized. Ongoing efforts in standardization, multi-institutional collaboration, and explainable AI development are encouraging steps toward overcoming these barriers.

In conclusion, AI-enhanced radiomics is poised to become an integral component of precision oncology. With continued methodological refinement, validation across diverse populations, and seamless integration into clinical workflows, it has the potential to transform cancer care by enabling more accurate, efficient, and personalized treatment strategies.

Conflict of Interest

Not available

Financial Support

Not available

References

1. Maniaci A, Rossi F, Bianchi L, Verdi M, Conti P, Romano G, *et al*. The integration of radiomics and artificial intelligence in clinical oncology: progress and future challenges. Cancers (Basel). 2024;16(5):1123-35.
2. Martell MB. Radiomics for lung cancer diagnosis, management, and personalized medicine: role of AI in improving detection, staging, and treatment prediction. Lung Cancer. 2025;190:107348-59.
3. Zhang P, Li Y, Sun Z, Wang H. Developments in artificial intelligence and radiomics for predicting recurrence risk, toxicity, and personalized treatment planning. Front Oncol. 2025;15:1459823-34.
4. Lee TF, Chang CH, Chi CH, Liu YH, Shao JC, Hsieh YW, *et al*. Utilizing radiomics and dosiomics with AI for precision prediction of radiation dermatitis in breast cancer patients. BMC Cancer. 2024;24:965-77.
5. Forghani R. Radiomics and artificial intelligence for biomarker and predictive modeling in oncology. Cancer J. 2019;25(4):254-62.
6. Yuan X, Xu H, Zhu J, Yang Z, Pan B, Wu L, *et al*. Artificial intelligence for image-based lung cancer classification and prognostic evaluation: a systematic review and meta-analysis. npj Precis Oncol. 2025;9:300-15.
7. Wang X, Zhou Y, Li M, Zhao J, Chen L, Sun H, *et al*. Multicenter development of a deep learning radiomics and dosiomics model to predict grade ≥2 radiation pneumonitis in non-small cell lung cancer. Sci Rep. 2025;15:12144-57.
8. Chilaca-Rosas MF, González-Santiago O, Martínez-Barajas A, Méndez-Romero C, Rodríguez-Hernández G. Systematic review and epistemic meta-analysis to advance AI-radiomics integration in glioma prognosis. Sci Rep. 2025;15:8421-33.
9. Tiwari A, Sinha A, Gupta V, Sharma N. Current AI technologies in cancer diagnostics and treatment: toward precision oncology and adaptive radiotherapy. Mol Cancer. 2025;24:55-67.

How to Cite This Article
Bakshi I. Utilizing AI in treatment planning and outcome prediction: Leveraging radiomics for personalized treatment analysis. International Journal of Radiology and Diagnostic Imaging 2025; 8(3): 146-149.